No Detail Found!

Immunohistochemical Expression of Cd10, Bcl6 and Mum1 in Differentiating Diffuse Large B Cell Lymphoma Subtypes.

Author(s)
Akhter Ali Bajwa Department of Pathology, Combined Military Hospital, Multan, Pakistan
Muhammad Tahir Khadim Department of Pathology, Combined Military Hospital, Multan, Pakistan
Hafeez Ud Din Department of Pathology, PNS Hospital Shifa, Karachi, Pakistan
Syed Salman Ali Department of Pathology, Combined Military Hospital, Multan, Pakistan
Unaiza Jamil Department of Pathology, Combined Military Hospital, Multan, Pakistan
Umair Aslam Shahzad Khan Department of Pathology, Combined Military Hospital, Lahore, Pakistan
Abstract
Objective: To determine the immunohistochemical expression of CD10, BCL6 and MUM1 in differentiating diffuse large B cell lymphoma subtypes. Study Design: Descriptive, cross-sectional study. Place and Duration of Study: Department of Histopathology, Armed Forces Institute of Pathology, Rawalpindi, from November 2014 to May 2015. Methodology: Newly diagnosed cases of DLBCL on H&E stain as well as IHC markers, according to WHO blue book 2008, were included in the study. Patients' gender, age and site of lymphoma were noted. DLBCL subtypes (GCB and activated type or non-GCB) were assessed based on IHC expression of CD10, BCL6 and MUM1 and the results were recorded. The data were analyzed by using computer software program SPSS version 20. Descriptive statistics, frequencies and percentages were calculated. Results: Out of 96 patients, 79 (82%) were male and 17 (18%) were female. Mean age was 54.66 ±16.73 years. Thirty-six (37.5%) cases showed positivity for CD10 and BCL6 both (GCB type), whereas MUM1 was positive in 60 (62.5%) cases (non-GCB type or activated type). A significant statistical association was seen between expression of IHC markers (CD10, BCL6 and MUM1) and DLBCL subtypes (GCB and non-GCB type, p<0.001). Conclusion: In Pakistani population, the frequency of non-GCB type expressing MUM1 is 62.5%, which is quite high as compared to western countries. It needs to be further explored, because it represents high-risk subsets in which alternative strategies for diagnosis and management should be planned.
Publication Details
Page(s) 621-624
DOI DOI not available
Published Journal: Journal of College of Physicians and Surgeons--Pakistan : JCPSP, Volume: 27, Issue: 10, Year: 2017

Request the full text from PASTIC

Keywords
BCL6. CD10. Diffuse large B cell lymphoma. Immunohistochemical expression. MUM1
References
HuhJ, 2012.Epidemiologic overview of malignant lymphoma,Korean J Hematol 47 92 -104
PervezS.,Non-Hodgkin Lymphoma, 2012.NHL) in Pakistan,Int J Mol Cell Med 1 62 -3
Hemandez-llizalituriFJ,DeebG,ZinzaniPL,PileriSA,MalikF,MaconWR, 2011.Higher response to lenalidomide in relapsed/refractory diffuse large B-cell lymphoma in nongerminal center B-cell-like than in germinal center B-celllike phenotype,Cancer 117 5058 -66
MenonMP,PittalugaS,JaffeES, 2012.The histological and biological spectrum of diffuse large B-cell lymphoma in the WHO classification,Cancer J 18 411 -20
GualcoG,WeissLM,HarringtonWJ, 2009.Nodal diffuse large B-cell lymphomas in children and adolescents: immunohistochemical expression patterns and c-MYC translocation in relation to clinical outcome,Am J Surg Pathol 33 1815 -22
GuoY,TakeuchiI,KarnanS,MiyataT,OshimaK,SetoM, 2014.Array-comparative genomic hybridization profiling of immunohistochemical subgroups of diffuse large B-cell lymphoma shows genomic alterations,Cancer Sci 105 481 -9
BahadirB,BehzatogluK,BektasS,BozkurtER,OzdamarSO, 2009.CD10 expression in urothelial carcinoma of the badder,Diagn Pathol 4 38 -
ShafferAL,EmreNCT,RomesserPB,StaudtLM, IRF4., -
ChenY,HanT,IqbalJ,IronsR,ChanWC,ZhuX, 2010.Diffuse large B-cell lymphoma in Chinese patients immuno-phenotypic and cytogenetic analysis of 124 cases,Am J Cli Pathol 133 305 -13
HabaraT,SatoY,TakataK,IwakiN,OkumuraH,SanobeH, 2012.Germinal center B-cell-like versus non-germinal center B-cell-like as important prognostic factor for localized nodal DLBCL,J Clin Exp Hematopathol 52 91 -9
YangZZ,NovakAJ,ZiesmerSC,WitzigTE,AnsellSM, 2007.CD70+ non-Hodgkin lymphoma B cells induce Foxp3 expression and regulatory function in intratumoral CD4+CD25 T cells,Blood 110 2537 -44
de LevalL,RickmanDS,ThielenC,ReyniesA,HuangYL,DelsolG, 2007.The gene expression profile of nodal peripheral T-cell lymphoma demonstrates a molecular link between angioimmunoblastic T-cell lymphoma (AITL) and follicular helper T (TFH) cells,Blood 1 4952 -63
NymanH,JerkemanM,Karjalainen-LindsbergM,BanhamAH,LeppaS., 2009.Prognostic impact of activated B-cell focused classification in diffuse large B-cell lymphoma patients treated with R-CHOP,Mod Pathol 22 1094 -101
HuangY,YeS,CaoY,LiZ,HuangJ,HuangH,CaiM,LuoR,LinT., 2012.Outcome of R-CHOP or CHOP regimen for germinal center and nongerminal center subtypes of diffuse large B-cell lymphoma of Chinese patients,Sci World J 8971 -8
Batlle-LópezA,GonzálezDV,MazorraF,MalatxeberriaS,SáezA,MontalbanC, 2016.Stratifying diffuse large B-cell lymphoma patients treated with chemoimmunotherapy: GCB/non-GCB by immunohistochemistry is still a robust and feasible marker,Oncotarget 5 18036 -49
HwangHS,YoonDH,SuhC,ParkCS,HuhJ, 2013.Prognostic value of immunohistochemical algorithms in gastrointestinal diffuse large B-cell lymphoma,Blood Res 48 266 -73
DaviesAJ,RosenwaldA,WrightG,LeeA,LastKW,WeisenburgerDD, 2007.Transformation of follicular lymphoma to diffuse large B-cell lymphoma proceeds by distinct oncogenic mechanisms,Br J Haematol 136 286 -93
ViscoC,LiY,Xu-MonetteZY,MirandaRN,GreenTM,LiY, 2012.Comprehensive gene expression profiling and immunohistochemical studies support application of immunophenotypic algorithm for molecular subtype classification in diffuse large B-cell lymphoma: A report from the International DLBCL rituximab-CHOP consortium program study,Leukemia 26 2103 -13
0

Citations

0

Downloads

66

Views